Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Company Overview More
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
CEO: Onsi J.D., Douglas E.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Futubull > Quotes > LPTX Leap Therapeutics > Detailed Quotes

LPTX Leap Therapeutics

Watchlist
1.200+0.010+0.84%
Close 05/26 20:00 ET
1.160-0.04-3.33%
Pre Mkt Price 05/27 08:54 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
1.220
Open
1.190
Turnover
921.56K
Low
1.160
Pre Close
1.190
Volume
770.55K
Market Cap
105.98M
P/E(TTM)
Loss
52wk High
4.170
Shares
88.32M
P/E(Static)
Loss
52wk Low
0.920
Float Cap
77.32M
Bid/Ask %
85.71%
Historical High
10.250
Shs Float
64.43M
Volume Ratio
1.21
Historical Low
0.573
Dividend TTM
--
Div Yield TTM
--
P/B
1.08
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.20%
Amplitude
5.04%
Avg Price
1.195
Lot Size
1
Float Cap
77.32M
Bid/Ask %
85.71%
Historical High
10.250
Shs Float
64.43M
Volume Ratio
1.21
Historical Low
0.573
Dividend TTM
--
P/B
1.08
Dividend LFY
--
Turnover Ratio
1.20%
Amplitude
5.04%
Avg Price
1.195
Lot Size
1
Price Forecast

No Data

News

Comment

Back to the Top